Joel Lewis Galectin Therapeutics Inc (GALT) insider trading activity

Joel Lewis is President and CEO of GALECTIN THERAPEUTICS INC. Currently has a direct ownership of 832,592 shares of GALT, which is worth approximately $4.58 Million. The most recent transaction as insider was on Dec 17, 2025, when has been sold 7,829 shares (Common Stock) at a price of $7.06 per share, resulting in proceeds of $55,272. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 833K

0% 3M change

7.18% 12M change

Total Value Held $4.58 Million

JOEL LEWIS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 17 2025	SELL Open market or private sale	$55,272 $7.06 p/Share	7,829 Reduced 0.93%	832,592 Common Stock
Dec 17 2025	BUY Exercise of conversion of derivative security	$22,390 $2.86 p/Share	7,829 Added 0.92%	840,421 Common Stock
Nov 18 2025	SELL Open market or private sale	$41,715 $6.15 p/Share	6,783 Reduced 0.81%	832,592 Common Stock
Nov 18 2025	BUY Exercise of conversion of derivative security	$16,211 $2.39 p/Share	6,783 Added 0.8%	839,375 Common Stock
Nov 17 2025	SELL Open market or private sale	$94,707 $6.04 p/Share	15,680 Reduced 1.85%	832,592 Common Stock
Nov 17 2025	BUY Exercise of conversion of derivative security	$37,475 $2.39 p/Share	15,680 Added 1.81%	848,272 Common Stock
Nov 10 2025	SELL Open market or private sale	$11,258 $6.03 p/Share	1,867 Reduced 0.22%	832,592 Common Stock

Nov 10 2025	BUY Exercise of conversion of derivative security	$4,462 $2.39 p/Share	1,867 Added 0.22%	834,459 Common Stock
Nov 05 2025	SELL Open market or private sale	$1,200 $6.0 p/Share	200 Reduced 0.02%	832,592 Common Stock
Nov 05 2025	BUY Exercise of conversion of derivative security	$478 $2.39 p/Share	200 Added 0.02%	832,792 Common Stock
Nov 04 2025	SELL Open market or private sale	$87,529 $6.07 p/Share	14,420 Reduced 1.7%	832,592 Common Stock
Nov 04 2025	BUY Exercise of conversion of derivative security	$34,463 $2.39 p/Share	14,420 Added 1.67%	847,012 Common Stock
Nov 03 2025	SELL Open market or private sale	$7,813 $6.01 p/Share	1,300 Reduced 0.16%	832,592 Common Stock
Nov 03 2025	BUY Exercise of conversion of derivative security	$3,107 $2.39 p/Share	1,300 Added 0.16%	833,892 Common Stock
Sep 12 2025	SELL Open market or private sale	$89,040 $6.36 p/Share	14,000 Reduced 1.65%	832,592 Common Stock
Sep 12 2025	BUY Exercise of conversion of derivative security	$33,460 $2.39 p/Share	14,000 Added 1.63%	846,592 Common Stock
Mar 03 2025	SELL Grant, award, or other acquisition	$88,579 $1.57 p/Share	56,420 Reduced 6.35%	832,592 Common Stock
Dec 23 2024	SELL Open market or private sale	$49,840 $0.89 p/Share	56,000 Reduced 5.88%	897,012 Common Stock
Dec 23 2024	BUY Exercise of conversion of derivative security	-	56,000 Added 5.55%	953,012 Common Stock
Mar 01 2024	SELL Grant, award, or other acquisition	$299,064 $1.96 p/Share	152,584 Reduced 14.53%	897,716 Common Stock
Dec 29 2023	BUY Grant, award, or other acquisition	$19,265 $1.66 p/Share	11,606 Added 1.1%	1,042,300 Common Stock
Dec 15 2023	BUY Grant, award, or other acquisition	$19,267 $1.6 p/Share	12,042 Added 1.15%	1,030,694 Common Stock
Nov 30 2023	BUY Grant, award, or other acquisition	$19,266 $1.95 p/Share	9,880 Added 0.96%	1,018,652 Common Stock
Nov 15 2023	BUY Grant, award, or other acquisition	$19,266 $1.87 p/Share	10,303 Added 1.01%	1,008,772 Common Stock
Oct 31 2023	BUY Grant, award, or other acquisition	$19,265 $2.04 p/Share	9,444 Added 0.94%	998,469 Common Stock

Joel Lewis

President and CEO

Norcross, GA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GALT shares.

Notify only if

Value

Insider Trading

Get notified when an Galectin Therapeutics Inc insider buys or sells GALT shares.

Notify only if

Operation

Value

Type

News

Receive news related to GALECTIN THERAPEUTICS INC

Track Activities on GALT

Account